AAVrh10-PCCA middle dose

Phase 1Gene therapy

MMayo Clinic

AAVrh10-PCCA middle dose is one of 2 therapeutic programs targeting Propionic Acidemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Propionic AcidemiaRecruiting

Propionic AcidemiaPhase 1

Recruiting

Competition

Competitive Landscape

1 competitor in Propionic Acidemia

#DrugCompanyPhaseTrials

Mrna-3927

Moderna

Phase 2

1 2

AAVrh10-PCCA middle dose

MMayo Clinic

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2033

Phase 1Recruiting

Propionic Acidemia

NCT07643844

Clinical

Trials by Indication[1]

Propionic Acidemia1 trial

Phase 1 Study of Intravenous Administration of a Serotype rh.10 Replication Deficient Adeno-associated Virus Gene Transfer Vector Expressing the Human Propionyl-CoA Carboxylase cDNA (AAVrh10-PCCA) to Individuals With Propionic Acidemia

Recruiting·MMayo Clinic·Phase 1·NCT07643844·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AAVrh10-PCCA middle dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for AAVrh10-PCCA middle dose. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Mayo Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Gene therapy
Highest Phase: Phase 1[1]
Company: MMayo Clinic

AAVrh10-PCCA middle dose

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2033

Trials by Indication[1]

Propionic Acidemia1 trial

References

Drug Info

Quick Facts

Related News